We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » MERCK DEFENDS VIOXX AGAINST CHARGES OF CARDIAC RISKS
MERCK DEFENDS VIOXX AGAINST CHARGES OF CARDIAC RISKS
August 26, 2004
An FDA-funded study of Merck arthritis drug Vioxx found that the popular drug may increase the risk of serious heart problems, but the company disputed the report’s findings as inconsistent with results from clinical trials.